6XCC
Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 21
6XCC の概要
エントリーDOI | 10.2210/pdb6xcc/pdb |
分子名称 | Botulinum neurotoxin type A, ZINC ION, N-hydroxy-5-sulfanylpentanamide, ... (4 entities in total) |
機能のキーワード | covalent inhibitor, hydroxamate, toxin, toxin-inhibitor complex, toxin/inhibitor |
由来する生物種 | Clostridium botulinum |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 50669.50 |
構造登録者 | |
主引用文献 | Lin, L.,Olson, M.E.,Sugane, T.,Turner, L.D.,Tararina, M.A.,Nielsen, A.L.,Kurbanov, E.K.,Pellett, S.,Johnson, E.A.,Cohen, S.M.,Allen, K.N.,Janda, K.D. Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A. J.Med.Chem., 63:11100-11120, 2020 Cited by PubMed Abstract: Botulinum neurotoxins have remarkable persistence (∼weeks to months in cells), outlasting the small-molecule inhibitors designed to target them. To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive warhead-were designed to leverage both affinity and reactivity. A series of first-generation bifunctional inhibitors was achieved through structure-based inhibitor design. Through X-ray crystallography, engagement of both the catalytic Zn and Cys165 was confirmed. A second-generation series improved on affinity by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and evaluation against the C165S mutant. Finally, a third-generation inhibitor was shown to have good cellular activity and low toxicity. In addition to our findings, an alternative method of modeling time-dependent inhibition that simplifies assay setup and allows comparison of inhibition models is discussed. PubMed: 32886509DOI: 10.1021/acs.jmedchem.0c01006 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.9 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード